Amgen’s Lowe on QbD, Process Scale and Standardization for Biopharma

Scale is a function of patient requirements and manufacturing productivity, says Amgen scientific executive director Duncan Lowe. Where QbD’s impact will be felt more is in facilitating equipment and knowledge transfer across sites. Gary Ritchie gets the Lowe-down in this IFPAC 2009 interview.